Akshay Thomas, MD
Retina Specialist · Nashville, TNNPI 1528324662
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (49.9%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 22 manufacturers reported payments, led by Genentech USA, Inc. at 42.9% of the total. Reporting peaked in 2022 at $25,588 and has fallen 60.2% since, to $10,179 in 2025.
Across 222 payments — averaging $488.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$46K
- Carl Zeiss Meditec, Inc.$12K
- Alimera Sciences, Inc.$11K
- Bausch & Lomb Americas Inc.$8K
- AbbVie$8K
- Eyepoint US, Inc.$6K
- plus $18K from 16 others
Across 66 payments — averaging $10,588 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$495K
- Eyepoint US, Inc.$94K
- Alimera Sciences, Inc.$81K
- ANI Pharmaceuticals, Inc.$29K
What the payments were for
- Consulting fees$54,06550%
- Speaking & faculty fees$39,20836%
- Travel & lodging$7,0787%
- Food & beverage$8,0137%
- Education$70%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 51 | $46,495 |
| Carl Zeiss Meditec, Inc. | 5 | $11,525 |
| Alimera Sciences, Inc. | 19 | $10,942 |
| Bausch & Lomb Americas Inc. | 9 | $7,918 |
| AbbVie(2 entities) | 26 | $7,854 |
| Eyepoint US, Inc. | 19 | $5,831 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 7 | $5,361 |
| Novartis | 9 | $5,073 |
| Regeneron | 7 | $2,982 |
| ANI Pharmaceuticals, Inc. | 4 | $2,090 |
| Regeneron Healthcare Solutions, Inc. | 15 | $442 |
| Astellas Pharma US Inc | 13 | $426 |
| Apellis Pharmaceuticals, Inc. | 17 | $411 |
| Biogen | 8 | $266 |
| Dutch Ophthalmic, USA | 2 | $166 |
| Coherus Oncology, Inc. | 2 | $159 |
| Neurotech Pharmaceuticals, Inc. | 1 | $125 |
| Ocular Therapeutix, Inc. | 2 | $121 |
| Genentech, Inc. | 2 | $90 |
| Harrow Eye, LLC | 2 | $61 |
| Mallinckrodt Enterprises LLC | 1 | $18 |
| Amgen | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VABYSMO$34,843
- Iluvien$9,398
- Clarus 700$8,500
- OZURDEX$7,272
- RETISERT$5,250
- YUTIQ$4,952
- BEOVU$4,800
- Lucentis$4,452
- EYP-1901$3,805
- CIRRUS HD-OCT$2,700
- CLARUS$300
- XIPERE$148
- EVA, combined machine$140
- TISSUEBLUE$140
- STELLARIS$138
- Cimerli$134
- EYLEA$122
- Izervay$101
How this compares
$108,371 in reported general payments places this provider in the 85th percentile of 58 retina specialist providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 74 | $542,760 |
| Prednisolone Acetate | 406 | $20,900 |
| Difluprednate | 165 | $15,496 |
| Mycophenolate Mofetil | 75 | $10,670 |
| ValacyclovirValacyclovir Hcl | 68 | $5,067 |
| Brimonidine Tartrate | 77 | $4,056 |
| Alphagan PBrimonidine Tartrate | 11 | $3,809 |
| Ketorolac Tromethamine | 136 | $3,782 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 219 | $3,570 |
| Atropine Sulfate | 31 | $1,335 |
| MethotrexateMethotrexate Sodium | 43 | $1,177 |
| Prednisone | 129 | $1,061 |
| Ciprofloxacin Hcl | 64 | $977 |
| Latanoprost | 85 | $774 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 11 | $593 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieAlphagan P | $7,854 | $3,80911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 58 retina specialist providers in Tennessee.
Other retina specialist in Nashville
- Carl AwhNashville$1.3M
- Peter SonkinNashville$949K
- Brandon BusbeeNashville$566K
- Eric SchneiderNashville$134K
- David ReichsteinNashville$114K
- Franco RecchiaNashville$72K
- Everton ArrindellNashville$39K
- Roy WallaceNashville$19K
- Kenneth MoffatNashville$17K
- Brigid MarshallNashville$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.